|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
20,430,000 |
Market
Cap: |
1.37(B) |
Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
52
Week Range: |
$38.04 - $69.69 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
250,132 |
394,694 |
1,191,358 |
1,409,424 |
Total Sell Value |
$16,523,610 |
$24,268,720 |
$69,977,407 |
$78,350,476 |
Total People Sold |
8 |
9 |
11 |
11 |
Total Sell Transactions |
21 |
39 |
80 |
83 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Carey Stephen P. |
Vice President and CFO |
|
2018-03-31 |
4 |
D |
$58.22 |
$29,518 |
D/D |
(507) |
6,118 |
|
- |
|
Marken James G. |
SVP Ops & Prod Dev |
|
2018-03-31 |
4 |
D |
$58.22 |
$16,185 |
D/D |
(278) |
65,192 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-31 |
4 |
D |
$58.22 |
$148,461 |
D/D |
(2,550) |
183,156 |
|
- |
|
Holubow Fred |
Director |
|
2018-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
14,811 |
|
- |
|
Raynor Daniel |
Director |
|
2018-03-19 |
4 |
S |
$60.62 |
$322,074 |
I/I |
(5,313) |
289,003 |
|
- |
|
Raynor Daniel |
Director |
|
2018-03-15 |
4 |
S |
$61.50 |
$116,973 |
I/I |
(1,902) |
294,316 |
|
- |
|
Marshbanks Tracy |
Director |
|
2018-03-14 |
4 |
S |
$63.10 |
$120,647 |
I/I |
(1,912) |
483,801 |
|
- |
|
Raynor Daniel |
Director |
|
2018-03-14 |
4 |
S |
$62.02 |
$119,016 |
I/I |
(1,919) |
296,218 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-14 |
4 |
S |
$62.03 |
$620,300 |
D/D |
(10,000) |
185,706 |
|
- |
|
Raynor Daniel |
Director |
|
2018-03-13 |
4 |
S |
$61.81 |
$1,123,023 |
I/I |
(18,117) |
298,137 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-13 |
4 |
S |
$61.52 |
$1,852,843 |
D/D |
(30,000) |
195,706 |
|
- |
|
Raynor Daniel |
Director |
|
2018-03-12 |
4 |
S |
$62.88 |
$498,513 |
I/I |
(7,928) |
316,254 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-12 |
4 |
OE |
$6.36 |
$99,998 |
D/D |
15,723 |
225,706 |
|
- |
|
Marshbanks Tracy |
Director |
|
2018-03-12 |
4 |
S |
$63.03 |
$773,315 |
I/I |
(12,269) |
485,713 |
|
- |
|
Marshbanks Tracy |
Director |
|
2018-03-09 |
4 |
S |
$63.01 |
$2,303,709 |
I/I |
(36,561) |
497,982 |
|
- |
|
Marshbanks Tracy |
Director |
|
2018-03-08 |
4 |
S |
$63.08 |
$970,864 |
I/I |
(15,391) |
534,543 |
|
- |
|
Marken James G. |
SVP Ops & Prod Dev |
|
2018-03-05 |
4 |
S |
$61.92 |
$258,640 |
D/D |
(4,177) |
65,470 |
|
- |
|
Marken James G. |
SVP Ops & Prod Dev |
|
2018-03-05 |
4 |
OE |
$6.36 |
$199,947 |
D/D |
18,001 |
69,647 |
|
- |
|
Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
|
2018-03-01 |
4 |
S |
$60.33 |
$1,766,771 |
D/D |
(28,652) |
12,938 |
|
- |
|
Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
|
2018-03-01 |
4 |
OE |
$28.76 |
$539,250 |
D/D |
18,750 |
41,590 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-01 |
4 |
S |
$60.59 |
$1,468,695 |
D/D |
(23,986) |
209,983 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2018-03-01 |
4 |
OE |
$6.36 |
$643,287 |
D/D |
23,986 |
233,969 |
|
- |
|
Przybyl Arthur |
President and CEO |
|
2017-05-22 |
4 |
D |
$47.01 |
$46,587 |
D/D |
(991) |
210,833 |
|
- |
|
Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
|
2017-05-22 |
4 |
D |
$47.01 |
$21,155 |
D/D |
(450) |
22,840 |
|
- |
|
Marken James G. |
SVP Ops & Prod Dev |
|
2017-05-22 |
4 |
D |
$47.01 |
$13,069 |
D/D |
(278) |
51,549 |
|
- |
|
399 Records found
|
|
Page 13 of 16 |
|
|